Infant acute lymphoblastic leukemia: Lessons learned and future directions

Area of Science:

• Pediatric Oncology
• Hematology
• Molecular Biology

Background:

• Infant acute lymphoblastic leukemia (ALL) presents a significant therapeutic challenge with poorer outcomes compared to older children.
• A high prevalence (approximately 80%) of mixed-lineage leukemia (MLL) gene rearrangements characterizes infant ALL, driving its aggressive nature.

Purpose of the Study:

• To highlight the challenges in treating infant ALL, particularly MLL-rearranged subtypes.
• To emphasize the need for improved therapeutic strategies to overcome early bone marrow relapse.

Main Methods:

• Review of current therapeutic approaches for infant ALL.
• Analysis of the biological underpinnings of MLL-rearranged ALL.
• Evaluation of treatment outcomes and relapse patterns.

Main Results:

• Current therapies achieve approximately 50% long-term event-free survival, but early bone marrow relapse remains a critical issue.
• MLL gene rearrangements are strongly associated with aggressive disease and poor prognosis in infant ALL.

Conclusions:

• Early intensification of chemotherapy and development of innovative therapies are essential for improving outcomes in infant ALL.
• Bone marrow transplantation should be reserved for a select group of high-risk patients.
• Emerging genetic and epigenetic insights into MLL-rearranged ALL offer promising avenues for future therapeutic development.